Novo Nordisk recently released its financial report for the third quarter of this year, showing that the company's revenue and profits have reached new highs. According to the financial report, Novo Nordisk's total revenue in the first three quarters was 166.398 billion Danish kroner (approximately 173.337 billion yuan), a year-on-year increase of 29%; The operating profit was DKK 75.808 billion (approximately RMB 78.969 billion), a year-on-year increase of 31%.
The company said that its performance growth was mainly driven by GLP-1 diabetes treatment and obesity treatment sectors. Its star products, Ozempic, Rybelsus, and Wegovy, had a total revenue of DKK 100.222 billion in the first three quarters.
From a regional perspective, the revenue of the United States in the first three quarters was 87.467 billion Danish kroner, a year-on-year increase of 46%; China's revenue in the first three quarters was DKK 13.269 billion, a year-on-year increase of 3%. At present, smeglutide is only approved for the treatment of diabetes in China.
In the field of GLP-1 diabetes treatment mentioned in the financial report, Novo Nordisk said that in the first three quarters of 2023, China's sales increased by 80% in Danish kroner and 95% in fixed exchange rate. This increase in sales reflects the use of Ozempic. The proportion of GLP-1 in the total prescription of diabetes increased from 2% 12 months ago to 3.3%.
Based on the good performance in the first three quarters, Novo Nordisk reiterated its previously raised annual sales and operating profit expectations in its financial report, with an expected annual sales growth of 32% to 38% and operating profit growth of 40% to 46%.